Business Context and Reporting Period
The filing is DanDrit Biotech USA, Inc. (formerly Putnam Hills Corp.), not Lunai Bioworks Inc. It is an unaudited Form 10-Q for the quarter and nine months ended September 30, 2014, filed November 13, 2014. DanDrit develops dendritic-cell cancer vaccines, primarily MelCancerVac (MCV) for colorectal cancer. On February 12, 2014, it completed a reverse acquisition of Danish operating company DanDrit Biotech A/S.
Key Financial Metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 in 2014; $925 in 2013 | $0 in 2014; $32,483 in 2013 |
| Gross loss | $(143,495) in 2014; $(15,273) in 2013 | $(225,500) in 2014; $(36,003) in 2013 |
| Operating loss | $(513,740) in 2014; $(339,261) in 2013 | $(1,493,948) in 2014; $(762,537) in 2013 |
| Net loss | $(535,243) in 2014; $(371,546) in 2013 | $(1,417,752) in 2014; $(1,114,563) in 2013 |
| Loss per share | $(0.07) in both periods | $(0.18) in 2014; $(0.21) in 2013 |
| Operating cash flow | $(1,102,968) for the first nine months of 2014; $(1,806,844) in 2013 |
Gross and operating margins are not meaningful because revenue was zero in 2014 while the company incurred substantial production and operating costs. Research and development costs included in cost of goods sold were $143,149 for the quarter and $221,550 for the nine-month period.
- Total assets were $2.55 million at September 30, 2014, compared with $450,467 at December 31, 2013.
- Cash was $597,744, and an additional $1.71 million was held in escrow for the stock offering.
- Total liabilities were $4.93 million, including $1.61 million of current related-party notes, $1.69 million of stock subscriptions held in escrow, $624,042 of accounts payable, and $1.01 million of accrued expenses.
- Stockholders’ deficiency was $(2.38) million, compared with $(1.68) million at December 31, 2013.
- Financing activities provided $1.39 million, including $752,806 of related-party borrowings and $725,500 from stock sales.
Material Changes Versus the Prior Comparable Period
- Revenue declined to zero from $925 for the quarter and from $32,483 for the nine months, reflecting limited compassionate-use sales in Singapore during the prior-year period.
- Nine-month gross loss increased to $225,500 from $36,003, primarily because of higher production and research costs without corresponding sales.
- Nine-month operating expenses increased 75% to $1.27 million, driven largely by equity-financing, legal, consulting, and related professional costs.
- Nine-month net loss increased 27% to $1.42 million. The prior-year period included larger interest expense, derivative gains, and debt-forgiveness gains.
- Common shares outstanding increased from 6.0 million at December 31, 2013 to 8.19 million at September 30, 2014, reflecting the reverse acquisition, recapitalization, and public offering activity.
- Foreign-currency translation produced a $230,701 gain in other comprehensive income for the first nine months of 2014, compared with a $133,365 loss in 2013.
Outlook, Risks, Contingencies, and Unusual Items
- Management disclosed substantial doubt about the company’s ability to continue as a going concern because of recurring losses and dependence on external financing. Management expected available equity and committed funding to support operations for the next 12 months, but profitability was not assured.
- After September 30, 2014, the company sold 889,690 shares for gross proceeds of $4.45 million, bringing total offering proceeds to $5.17 million through October 23, 2014. Outstanding shares reached 9.07 million.
- The company repaid approximately $814,000 of Paseco related-party loans, including accrued interest, in October 2014.
- At September 30, 2014, all $1.61 million of related-party notes were classified as current, with most due February 1, 2015 or extendable at higher interest rates. The company also had an approximately $339,288 related-party funding commitment through February 2015.
- On October 1, 2014, DanDrit entered into a collaboration with San Martino Hospital for a planned Phase III study of MCV in disease-free stage IV colorectal cancer patients.
- MCV was not approved for general sale and had only limited compassionate-use sales. FDA approval, clinical efficacy, manufacturing compliance, product liability, and future financing remain significant risks.
- The company reported no material pending legal proceedings, although it described a disputed claim by a Danish law firm of approximately $33,421.
- The company had approximately $10.2 million of Danish and $120,000 of U.S. federal net operating loss carryforwards, but recorded a full valuation allowance against deferred tax assets.
Investor Verification Items
- Confirm the issuer identity and ticker because the supplied metadata names Lunai Bioworks Inc., while the filing identifies DanDrit Biotech USA, Inc.
- Verify the use, release, and remaining balance of offering proceeds held in escrow and the subsequent $4.45 million of equity proceeds.
- Assess liquidity after repayment of the Paseco loans and the maturity or extension terms of the remaining related-party debt.
- Review the going-concern conclusion and determine whether recurring external financing can support operations absent commercial revenue.
- Validate the status, design, funding, and regulatory pathway of the planned Phase III MCV clinical trial.
- Reconcile share counts, including shares reserved for non-consenting Danish shareholders and the dilution from the public offering.